Generate Biomedicines (NASDAQ:GENB) Coverage Initiated at Guggenheim

Key Points

• Guggenheim initiated coverage on Generate Biomedicines with a buy rating and a $30 price target, implying about a 139.62% upside from the current share price.
• Market consensus is a Buy with a $30 consensus price target; Cantor Fitzgerald also started coverage with an "overweight" rating while Wall Street Zen recently moved the stock to "hold."
• Generate Biomedicines applies machine learning and generative artificial intelligence to design and optimize protein sequences and other biological molecules for therapeutic discovery.

Guggenheim initiated coverage on shares of Generate Biomedicines (NASDAQ:GENB - Get Free Report) in a research note issued on Tuesday,Benzinga reports. The firm set a "buy" rating and a $30.00 price target on the stock. Guggenheim's price target suggests a potential upside of 139.62% from the stock's current price.

A number of other equities research analysts also recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Generate Biomedicines in a research note on Tuesday. They set an "overweight" rating on the stock. Wall Street Zen upgraded shares of Generate Biomedicines to a "hold" rating in a research note on Saturday, March 14th. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, Generate Biomedicines presently has a consensus rating of "Buy" and a consensus price target of $30.00.

Generate Biomedicines Price Performance

GENB opened at $12.52 on Tuesday. Generate Biomedicines has a 1 year low of $11.00 and a 1 year high of $15.32.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.